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ABSTRACT
Healthy amounts of sleep is vital for normal human functions such as daily
learning, memory, emotional state and cardiovascular function. Studies conducted
previously have shown sleep deprivation to be associated with increases in sympathetic
activity contributing to autonomic nervous system (ANS) dysregulation. HRV
biofeedback (HRVB) training induces HRV coherence, a condition that maximizes HRV
and facilitates autonomic and cardiorespiratory homeostasis. This randomized,
controlled, intervention trial will test the hypothesis that HRVB can improve HRV
coherence and increase overall sleep quality. Patients are randomized to previously
established HRVB or sham protocols (n=40 each, total planned enrollment N=80). Each
participant completes a baseline assessment, 6 weekly training sessions, a post-training
assessment, a booster training session and assessment (1-month post-training), and a
follow-up assessment (2 months post-training). Wrist actigraphy is used to obtain
continuous rest/activity recordings 24-hours per day over three 1-week periods coinciding
with the baseline, post-treatment, and follow-up assessments. Subjective sleep symptoms
are included at each assessment using the Pittsburg Sleep Quality Index (PSQI).
Outcomes include: 15-minute resting HRV recordings (HRV Coherence Ratio), as well
as subjective (total PSQI and sleep quality scores) and quantitative sleep measures
(actigraphic sleep onset latency, duration, efficiency, wake after sleep onset). To date, 85
patients completed their baseline assessment; 63 completed their post-training
assessment, and 50 completed the entire protocol. In preliminary analyses, HRVB
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patients had elevated mean (±SD) HRV Coherence Ratios at the post-training assessment
relative to baseline (0.11±.02 vs. 0.27±0.05, n=43, p<0.001), whereas no differences were
observed among controls (0.10±0.02 vs. 0.12±0.02, n=41, p=0.97). Compared to baseline
scores PSQI Global Score was reduced at Post Assessment (12.3±0.5 vs 11.1±0.6 n=31,
p=0.02) and at Follow-up Assessment (12.3±0.5 vs 10.3±0.9 n=25, p<0.001); no
differences among controls. Compared to baseline scores Sleep Duration elevated at Post
Assessment (436±15 vs 465±19 n=23, p=0.03) and at Follow-up Assessment (436±15 vs
479±19 n=21, p=0.02); no differences among controls. Preliminary results indicate
receipt and persistence of intervention among HRVB participants to date. Results show
evidence of Subjective (PSQI) and Objective (Duration) sleep improvements. HRVB is a
valid, quantifiable, easily-implemented procedure; and previous research suggests that
HRVB can improve overall sleep quality.
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CHAPTER 1
INTRODUCTION AND SPECIFIC AIMS

Poor sleep quality can lead to insomnia, fatigue, cognitive disturbance, and
depression.1,2 Overall quality of sleep in the United States has taken a toll with 50% of
people age 55 years and older reporting problems with their routine sleep schedule.3
Sleep has shown to be vital for functions such as development of physiological systems,
learning, memory, emotional state, cardiovascular and metabolic function and cellular
toxin removal.4 Epidemiological studies have identified associations between short sleep
duration (less than ~7 hours per 24-hour period) and chronic diseases such as diabetes,
obesity, depression, hypertension, cardiovascular disease, stroke, cancer, and all-cause
mortality, with at least some studies showing the elderly being particularly
susceptible.1,2,5–7 Diminished or reduced heart rate variability (HRV), the variation of
heart rate over time, has been linked to cardiovascular disease, decreased immune system
function, diabetes, poor sleep quality, and premature death.8,9 However, improving an
individual’s HRV with biofeedback (HRV-B) can elicit improvements in depressive
symptoms, chronic pain, immune system function, overall autonomic nervous system
(ANS) function, and sleep issues.10–12
HRV-B is a technique used to increase an individual’s HRV through a noninvasive, nonpharmacological paced breathing exercise. Subjects trained in HRV-B
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perform slow, paced diaphragmatic breathing to achieve HRV coherence. While in
coherence, one can observe waveforms from breathing that are synchronized with the rise
and fall of the heart rate. As one inhales the heart rate increases and the heart rate
decreases with exhalation. An individual achieving HRV coherence typically reports
feelings of joy, resilience, mindfulness, and hope. This technique is typically taught by a
trained coach and uses visual feedback through a computer screen to achieve the resonant
frequency of breathing. The resonant frequency is the breathing rate needed to acquire a
sinusoidal waveform of increasing and decreasing heart rate that is synchronized with the
breath, usually at a frequency of ~5-6 breaths per minute, that corresponds with a state of
HRV coherence.8,13 HRV coherence is a normal physiological state that amplifies HRV.13
During sleep, parasympathetic nervous system activity dominates, HRV is heightened,
specifically during non-rapid eye movement (NREM) sleep, and HRV coherence likely
occurs naturally due to cardiorespiratory coupling, which heightens heart rate
variability.14,15 While sleeping, we breathe at a slower rate, in particular during NREM
sleep. During REM sleep ~5-7 breaths per minute are taken and the ANS exhibits
sympathetic dominance.16,17 Once the resonant frequency of breathing is achieved,
individuals will begin to improve their own HRV by being in coherence on demand,
which in turn can help them self-regulate to improve symptoms of stress, anxiety, fatigue
or depression that have been associated with low HRV, by bringing balance to the ANS.
The restorative properties of sleep also are likely associated with the cardiorespiratory
coupling that occurs naturally during sleep.18
It is important to understand the role HRV-B can play in improving an
individual’s overall sleep quality. Low HRV has been found to be associated with
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reduced sleep quality.19 If HRV-B can improve sleep quality, then, a relatively simple,
but effective technique can be implemented among individuals with sleep disturbances.
Thus, previous studies have shown that HRV-B may serve as a useful alternative
treatment among individuals suffering from insomnia or other sleep disorders.7,9,19–21
This study used data collected from Veterans patients with chronic pain
participating in a study conducted at the Wm. Jennings Bryan Dorn Veterans Affairs
Medical Center (DVAMC). Data collection included questionnaires to obtain
information on psychometric outcomes including pain, stress, depression, fatigue, sleep
quality, cognitive function, as well as sociodemographic data and other potential
confounding factors. Eligible participants included DVAMC patients above the age of
18, who were English literate and are currently experiencing chronic pain.
In this randomized, sham-controlled, behavioral intervention trial, data collected
from June 2016 to February 2019 was included in this analysis. The target sample size
was to enroll 80 Veterans with chronic pain currently being treated at Dorn Veterans
Affairs Medical Clinic. Eligible Veterans who were willing to participate provided
written informed consent, after which they were enrolled and randomized into the HRVB intervention or sham group. Participants completed a 16-week intervention. Veterans
were randomized after consent and assigned to the treatment group or the control group.
If randomized into the control group Veterans completed a 16-week sham protocol that
did not include any HRV-B. At baseline, a 15-minute resting HRV recording was
obtained, and sleep was assessed via a questionnaire and one week of wrist actigraphy.
During weeks 1-7, the intervention group was given HRV-B via a trained and qualified
coach. Participants engaged in weekly sessions that included their respirations being
3

monitored, their heart rate observed via a photoplethysmography (PPG) and were
instructed to breathe a 5-6 breathes per minute. During this instruction the form of
inhalation and exhalation was critiqued and corrected, if needed. The control group
received sham training where their pulse and respirations are monitored while they
passively view static nature slides on a computer screen. They are instructed to ‘just
relax’ and picture themselves in a state of relaxation within the images. After the 6
weekly training sessions, subjects were reassessed using the same outcome
measurements. On week 12, subjects received a HRVB ‘booster’ training session, had
their HRV measured, and completed the questionnaire again. However, they do not
receive a sleep actigraphy monitor. The final follow-up visit occurred on week 16, and
all outcomes were measures one last time. The Pittsburg Sleep Quality Index (PSQI)
and wrist actigraphy are previously validated sleep measures..22
Statistical analysie examined the relationship between sleep quality and HRV
using generalized linear mixed models for repeated measures (PROC MIXED in SAS).
This study tested the hypothesis that HRV-B training will improve sleep quality (total
PSQI score and sleep quality subscore), and actigraphic sleep efficiency, sleep onset
latency, wake after sleep onset and sleep duration compared to the sham control group.
The primary objective of this study was to determine if HRV-B can improve overall sleep
quality via wrist actigraphy and perceived sleep quality among DVAMC patients with
chronic pain.
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The specific aims of this study were to:
1.

Determine if a 6-week regimen of HRV-B training improves subjective sleep

symptoms (Pittsburg’s Sleep Quality Index’s Global Sleep Score) relative to a sham
control group.
2. Determine if a 6-week regimen of HRV-B training improves objective sleep measures
(Sleep duration, Sleep efficiency, Sleep onset latency, wake after sleep onset) relative to a
sham control group.
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CHAPTER 2
BACKGROUND

Autonomic Nervous System
The ANS is involved in many bodily functions including energy metabolism,
regulation of the cardiovascular system and makes significant contributions to overall
physiological homeostasis. This system operates without our conscious, voluntary
control.23 Within this branch of the nervous system are two divisions, the sympathetic
and parasympathetic nervous systems. The sympathetic nervous system (SNS) controls
the “fight -or- flight response. When activated it can increase heart rate, dilate pupils,
slow down digestive activity, and inject adrenaline into the bloodstream. This system
allows the body to be prepared to conduct strenuous physical activity by delivering
oxygenated blood to the tissues that need it, predominately the skeletal muscles.
Furthermore, the parasympathetic nervous system (PNS) allows the body to rest and
recover from all things related to daily living.23 The PNS dominates during quiet, resting
conditions. The overall role of the PNS is for individuals to converse and store energy
and continue regulation of bodily functions just as urine production, digestion and
recovery.23 Sympathetic dominance can be seen from stressors of daily life.
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Parasympathetic dominance can be seen while being involved in relaxing activities and
especially while sleeping.
Sleep-related changes in ANS has been investigated and reported. During sleep, a
reduction in sympathetic activity, during non-rapid eye movement stage of sleep, has
been shown using interbeat intervals (IBI).20 Whereas, during REM sleep sympathetic
activity spikes back towards waking period levels.20 It has also been reported that an
increase in HR and blood pressure (BP) during REM sleep occur, indicating increased
levels of sympathetic influence.20 Another study in fibromyalgia patients showed that
pain from this disease increases sympathetic activity causing these patients overall sleep
efficiency and overall quality to be significantly reduced.24 Over-stimulation of the SNS
causes an imbalance of the ANS which can result in restlessness and overall poor sleep
quality due to sympathetic dominance. Rebalancing the ANS through HRV-B may lead
to improvement to overall sleep quality.24

Sleep
The physiological function of sleep is not entirely understood. Human physiology
is driven by what are called circadian rhythms, which are generated centrally in the
hypothalamus and synchronized to the ambient light-dark cycle via the retina, optic
nerve, and suprachiasmatic nuclei.4 Sleep is a cyclical process that is essential to human
functionality. While we sleep, we have increased protein formation and synthesis. This
restoration involves parasympathetic dominance. The circadian rhythm maintained by
the hypothalamus keeps a bodily schedule of gland secretion for sleep regulating
hormones like melatonin. There is also a homeostatic sleep rhythm of the sleep-wake
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cycle. This cycle acts as a counter or a balance to when and how long we sleep.25 The
circadian rhythm for sleep is primarily responsible for when an individual generally goes
to sleep and wakes up. However, this may not always be followed, such as someone who
works the night shift or stays up late to complete a task. Sleep-wake homeostasis works
to effectively be a timer of sleep regardless of when you normally sleep.25 Sleep-wake
homeostasis will remind the body it needs to rest after a certain amount of time through
the use of an endogenous chemical, primarily adenosine. Essentially, it makes the desire
to sleep greater the longer we have been awake and ultimately the likelihood of falling
asleep increases. Sleep-wake processes work bidirectionally in that the longer one
remains asleep, the more likely an individual will awaken. The sleep-wake cycle can
take precedent for someone who generally goes to sleep late and wakes up late. If this
individual were to go to bed much earlier after a long day, they may not wake up as late
as they normally would because the likelihood of sleeping into double digit hours is
reduced due to this mechanism.25
Sleep stages can be divided into NREM and rapid-eye-movement (REM)
sleep.2,26 REM periods can last from 10 minutes up to 1-hour long. The average person
will cycle through these stages of sleep four to five times per night. NREM is thought to
be helpful for rebuilding the body whereas REM is thought to be focused on the brain.
Previous studies have shown that deprivation of REM sleep can lead to hallucinations,
short-term personality changes and paranoia.2
The relationship between autonomic dysfunction and disrupted sleep has not been
thoroughly examined. Studies conducted previously have shown that sleep deprivation
can cause an increase in sympathetic ANS activity.27 During sleep is a good time to
8

assess ANS function as the heart rate is primarily under PNS control.27 Cardiovascular
autonomic control plays a crucial part in the integrity of sleep quality. Tobaldini also
concluded that analysis of HRV can play a key role in being a non-invasive tool for
providing information on autonomic changes that would lead to sleep disturbances.28
Sleep deprivation throws off the ANS creating an asymmetry of PNS and SNS
activity. By increasing a sympathetic dominance over the parasympathetic system an
imbalance of the system is created leading to a lack of flexibility to respond to emotional
challenges such as stress on a regular basis.27 The restorative properties of deep sleep are
related to the resonance frequency of breathing, cardiorespiratory coupling, and
parasympathetic dominance that typically occur during non-rapid eye movement
(NREM) and slow-wave sleep.14 In a study conducted on shift working nurses, those
working the night shift had autonomic dysregulation as compared to the day shift nurses
during their sleep periods. Measurement of HRV coherence during sleep may serve as an
indicator of ANS dysfunction within individuals.14

HRV & HRV-B
HRV is the variability between consecutive heartbeats. By recording the time
between individual heartbeats, the IBI can be used for measuring HRV.18,29,30 Variation
in the IBI is controlled by the SNS and PNS portions of the ANS. Respiratory sinus
arrhythmia (RSA) is the variation in heart rate that occurs during one respiratory cycle.
The RSA is characterized by an increase in sympathetic activity when inhaling, which
increases heart rate, and parasympathetic activity when exhaling, which decreases the
heart rate.31 Practice with HRV is designed to strengthen baroreflexes which ultimately
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will improve the ANS balance of parasympathetic and sympathetic activity.32
Individuals with anxiety, high stress, sleep issues, chronic pain, and depression have been
shown to have diminished HRV.18,29,32 In previous studies, HRV-B has demonstrated an
ability to alleviate symptoms of both mental and physical disorders involving the ANS.33
HRV-B is conducted through individual training using a paced breathing exercise.
HRV-B is an interactive procedure whereby participants engage in training to increase
their HRV in real time. HRV-B is a complementary technique that can be used in unison
with other non-pharmacological techniques such as yoga, cardiorespiratory activity, and
meditation.9 When introducing HRV-B to a new patient, trainers instruct them to
breathe deeply with their stomach, also called belly breathing, and regulate their
breathing rate at 5-6 breaths per minute, which is at 0.1 Hz. By doing this consistently
participants learn how to increase their parasympathetic activity which concurrently
reduces sympathetic activity.
Pharmacology interventions are available for sleep issues, but non-pharmaceutical
approaches are desirable. HRV-B is a valid technique that may improve autonomic
function. Previous studies have shown HRV-B to positively impact overall sleep quality.
A case study by a medical provider in a combat zone reported improved sleep after using
a portable biofeedback device.12 Another study used HRV-B in a randomized controlled
trial study design in Amsterdam. This study compared HRV-B with other stress relief
strategies and found improvements in overall sleep quality after a 5-week HRV-B
training including home practice.9 Additionally, a randomized clinical trial conducted by
Sakakibara et al. found that HRV-B training increased PNS activity during sleep.33 This
result was found by analyzing HRV-B during sleep and observing an increase at follow10

up that the high-frequency component of HRV, the component associated with PNS
activity, was heightened.33 This experimental epidemiological randomized control trial
sought to examine the relationship between sleep quality and HRV-B.

HRV, HRV-B & Sleep
The HRV of an individual is a useful measure of an individual’s autonomic
health. By measuring HRV, we can determine the overall health of the ANS. Reduced
HRV indicates overstimulation of the SNS and dominance over the PNS. Increased HRV
shows a balance between the two systems or even parasympathetic dominance.
While we sleep the expectation is for HRV to increase due to parasympathetic
dominance, which is required to begin the physiological restoration that occurs while
sleeping. This increased parasympathetic dominance allows the body to conduct the
growth and repair previously stated. Also, this parasympathetic dominance is important
for restful uninhibited sleep. However, if the PNS is unable to obtain dominance due to
sympathetic dominance sleep disturbances can begin to arise. The inability to sleep
through the night or inability to fall asleep can be experienced due to the SNS dominance.
Sleep can be thought of like a seesaw effect. While sympathetic activity increases during
the REM cycle, which will increase BP and improve blood flow to the brain,
parasympathetic dominance does not occur. Likewise, when parasympathetic dominance
is occurring during NREM, the restorative properties of sleep occur.25
HRV-B can play a critical role in addressing sympathetic nervous system
dominance that plagues many individuals. HRV-B could be used to tame sympathetic
nervous system dominance during an individual’s daily life. Balancing this during the
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waking periods allows an individual to have parasympathetic dominance during sleep
periods. We theorize, an increase in an individual’s HRV during waking periods and
sleep periods can show an improvement in autonomic health. This improvement could
lead to an overall improvement in an individual’s sleep patterns.

Characterization of Sleep
Wrist actigraphy can be used to measure a person’s sleep and wake cycle as well
as a subject’s rest/activity rhythms. An actiwatch measures activity through means of a
piezo-electric accelerometer that is set to record the integration of intensity, amount and
duration of movement in all directions. This study used Motionlogger WatchWare
version 1.99.5.1 for actigraphy analysis (AMI, Ardsley,NY). The actiwatch device has a
maximum sampling frequency of 32 Hz and will record all movements above a g-force of
0.05g.34 These actiwatches are useful for recording objective measures on an individual’s
sleep and is rapidly developing as a significant asset for measuring sleep quality and
assessing sleep disorders. A research assistant manually identifies the beginning and end
of each sleep interval, which is then used to obtain sleep summary measures.35
Wrist actigraphy has been validated in numerous studies.36 Esbensen et al. aimed
to validate wrist actigraphy within a pediatric down syndrome population. Using wrist
actigraphy, compared against the gold standard polysomnography, this study validated
the watches results suggesting the data from them is sensitive in measuring duration and
efficiency.36 Another pediatric study used wrist actigraphy on children with atopic
dermatitis and validated their results with the questionnaires completed.37 Wrist
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actigraphy as a tool to quantify sleep quality is a cheaper, less invasive, more accessible
and valid option to researchers and participants.
Many sleep variables can be considered within a given sleep interval. However,
some of the most important objective measures identified are: amount of sleep (sleep
duration), the amount of time asleep compared to total time in bed (sleep efficiency), how
long does it take for you to fall asleep once you are attempting to fall asleep (sleep onset
latency) and finally the amount of minutes spent awake during the sleep period (wake
after sleep onset). An individual’s sleep duration is a measure of the length of time spent
sleeping each night.38 Sleep duration is calculated by creating a down interval that is set
by determining the point of sleep beginning and the point in which sleep ends. The down
interval is determined by the research assistant processing the accelerometers (AMI,
Ardsley, NY). An individual’s sleep efficiency is the ratio of the total time spent asleep
compared to the total amount of time spent in bed.38 Sleep efficiency is calculated with
the following equation (100*Sleep Duration (O-O Duration)). The O-O Duration is
calculated with a sub-interval of the Down Interval that estimates the true sleep period. It
represents the time from sleep Onset (as defined by the sleep latency) to sleep Offset (the
end of the last sleep episode in the Down Interval). Thus, an O-O interval represents the
Down Interval minus the sleep latency and any terminal wake in the down interval.39
Essentially, sleep onset latency is the period between where the research assistant sets the
beginning of sleep and where the software begins the O-O interval. Wake after sleep
onset refers to the period of wakefulness occurring during the O-O interval.38 Wake after
sleep onset is calculated by adding the total minutes of wakefulness that occurs during the
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O-O interval. Typically, these measures can categorize the participants as poor, average
and good sleepers.
A score of 85% or greater is considered to be good sleep efficiency.40 A score of
75 and below is considered poor sleep. A score between 75 and 85 is considered average
sleep.40 Sleep duration greater than 420 minutes is considered good sleep. Sleep
duration less than 360 minutes is considered poor sleep. Sleep duration between good
sleep and poor sleep is considered average.40 Sleep onset latency (SOL) and wake after
sleep onset (WASO) are expected to decrease for sleep improvement.41 An increase in
efficiency and duration into the good range is expected for improved sleep. Using wrist
actigraphy data, insomnia may be defined using the following cut-off values: sleep onset
latency >12 minutes, total sleep time <440 minutes, WASO >25 minutes, sleep efficiency
<92%.7,42
The Pittsburg Sleep Quality Index was developed at the University of Pittsburg
and is currently the most used sleep inventory questionnaire available. Subjective
measures of sleep can be obtained using the PSQI questionnaire.40 It refers to usual
sleep habits over the past 30 days. The PSQI also has subsections that allow it to take
into account days at work and days away from work.22 In the PSQI questionnaire, there
are 19 questions, composed of 7 subscales, that create a total overall score. The PSQI
generally takes around 5-10 minutes to complete, offering a quick and accurate way to
assess an individual’s overall sleep quality.43 The validity of the PSQI has been tested in
a multitude of studies each of which have found the PSQI to be consistent and internally
valid.44–46
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CHAPTER 3
METHODS

In this study, a previously approved, standardized HRV-B intervention protocol
was used to deliver the HRV-B intervention. Data from the intervention group were
compared to a sham control group over the 16-week intervention period. The Dorn VA
institutional review board approved this study. All participants gave informed consent
prior to participation. The Veterans Affairs Office of Research and Development funded
this study (Grant number: I01BX007080). This study was prospectively registered
(clinical trial number NCT02426476).
The experimental design included four assessments over a 16-week study period
(Appendix A, Figure A1). The initial visit (baseline) occurred on the same day of consent
and included a 15-minute resting HRV recording, and a symptom questionnaire. Subjects
were sent home with an actiwatch for a 1-week sleep outcome assessment. The
following six weeks involved group specific training. On the seventh week, after six
training visits post-training took place, remeasuring of all outcomes measured at baseline
took place. One-month post-training, a booster assessment occurred that included a 15minute HRV recording and symptoms questionnaire, although no wrist actigraphy was
measured. Finally, one month after the booster was a follow-up assessment. Saliva was
collected at the conclusion of each assessment, excluding the booster assessment, and
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stored in a freezer at -80°C.
Eligibility, Participants, and Recruitment
The study population was comprised of Veteran patients experiencing chronic
pain who lived in the Columbia, South Carolina area. Flyers with pull tabs advertising
the study were distributed around Dorn Veterans Affairs Medical Center (DVAMC).
Subjects were recruited who were: English literate, ≥18 years old, of any race, ethnicity,
or sex meeting inclusion and exclusion criteria. Additionally, eligibility was checked,
patients were telephoned to ascertain interest in the study and perform the chronic pain
eligibility screen (Pain Screening Questionnaire, Vanderbilt University Medical Center,
Center for Quality Aging, Nashville, TN). The pain screening instrument assessed pain
using the following questions: 1.) Do you have pain anywhere right now? 2.) Does pain
ever keep you from sleeping at night? 3.) Does your pain ever keep you from
participating in activities/doing things you enjoy? 4.) Do you have pain every day?
Chronic pain was determined to be present if the patient answered yes to questions 1-3, or
to question 4 alone. Recruitment targeted patients in the Pain Clinic, and the
Rehabilitative Medicine and Rheumatology and primary care department at the DVAMC.
Initially, participation in the study included ten reimbursements ($20 per visit or $200
total for protocol completion), and towards the end of the study, supplemental funding
was provided to increase recruitment and retention, and $30 per visit was offered along
with a $10 travel reimbursement ($400 total).
Veterans were excluded if their participation would not be appropriate from a
safety standpoint; if they had a health condition or medication use that could bias their
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HRV measures; or if they were considered cognitively incapable of completing the
protocol. The following exclusions were applied: a) history of arrhythmias requiring
medication and/or hospitalization, including supraventricular tachycardia or atrial
arrhythmias (e.g., atrial fibrillation); b) Veterans with a pacemaker or automatic
implantable cardioverter-defibrillator; c) history of an acute coronary syndrome,
revascularization, thrombolytic or other therapy related to ischemic heart disease; d)
uncontrolled hypertension (systolic blood pressure <140 mmHg, diastolic blood pressure
<90 mmHg), although patients with well-controlled hypertension (no change in
medications for 6 months) were not be excluded; e) history of heart transplant or
cardiovascular surgery within 1 year; f) Veterans receiving beta-adrenergic antagonists;
g) Veterans receiving non-dihydropyridine calcium channel blockers; h) Veterans
receiving an antagonist of the renin-angiotensin-aldosterone system were eligible if their
medication profile was stable; i) Veterans with New York Heart Association class 3 or 4
congestive heart failure; j) history of seizure disorder or use of antiseizure or
anticonvulsant medication; k) cognitive impairment (e.g., dementia), or a history of
acquired neurocognitive deficit, or central nervous system or neurological disorder (e.g.,
Gulf War Syndrome); l) moderate or severe head injury or stroke; m) evidence of active
substance abuse or dependence (alcohol or tobacco use was not an exclusion, Veterans
will be asked to report their use via questionnaire); n) life history of bipolar, psychotic,
panic or obsessive-compulsive disorder (history of depression will not be an exclusion).
Random Allocation to Conditions
Random assignment to the 6-week HRV-B treatment or sham intervention group
was performed prior to the baseline assessment using a permuted block randomization
17

procedure, with a block size of 4 and no stratification. Thus, for example, assuming 20
patients are to be assigned either to sham (S) or biofeedback, and two patients will be
assigned each to the (S) treatment and two to the biofeedback by randomly selecting one
of six possible permutations of the two treatments in blocks of four. The treatment
assignment was determined before any patient was enrolled into the study and the
documentation and assignment of each patient was kept confidential. This was a singleblinded study and only the HRV-B trainer was aware of group assignment. Research
participants were blinded to their group assignment of each participant. At the
conclusion of the study, sham participants were told that they would be offered a “crossover training” after completion of their protocol. If interested, sham participants were
provided with one session of HRV-B training in the same manner as the intervention
group.
Intervention
Participants in the two intervention arms both received an introduction to the
study including reimbursement, the study timeline, and the process of data collection.
The HRV-B training consisted of a 15-minute resting period that included an HRV
recording, and a 25-minute period of biofeedback training and coaching. Participants
were fitted with HRV monitoring equipment and were instructed to sit quietly for 15
minutes in a relaxed posture, viewing a series of neutral nature scenes on a computer
monitor without any text or stimulating or confrontational content, changing at 40-second
intervals. Patients were instructed to ‘just relax’, or ‘take it easy’ during this time. The
HRV-B portion of the training involved a trained and qualified biofeedback coach to
instruct the participant on two primary techniques. The first was to paint relaxing
18

imagery into the participant’s mind and help guide them to thoughts that were stress-free,
and they found relaxing in their day to day lives. The second part was to adjust the
breathing pattern as well as the rate. This involved instructions such as diaphragmatic
breathing (aka “belly breathing”) with the abdomen to have full use of the diaphragm,
breathing deeply through the nose and out through pursed lips, to use good posture while
breathing, avoiding slouching, and including a good transition between inhaling and
exhaling. Through coaching, participants were able to slow their breathing to ~6 breaths
per minute which over time synchronized their heart rate oscillations with their breathing,
ultimately allowing the participant to get into a state of ‘HRV coherence’. This state
could be visualized by the patient on the computer monitor using the biofeedback
equipment. The synchronization observed was the increase of the heart rate oscillations
during inhalation and a decrease in heart rate oscillations during exhalation (i.e., zero
phase between breathing and heart rate). Home practice was administered for a minimum
of 10 minutes daily. The participant was issued an Emwave 2 device or an attachment
that took advantage of the Innerbalance phone application. Instructions on when to
practice the intervention technique was described as times of high stress, feelings of
frustration or when attempting to go to sleep at night. Intervention group practice
minutes were recorded via download from the device used as well as self-report on
average time practiced per day over a 1-week period, at each training session. Sham
participants were asked how much time they practiced with the squeeze ball and relaxed
per day over a 1-week period, at each training assessment.
Patients in the sham condition used the same training equipment as the
intervention group however they were asked to ‘just relax’ or ‘take it easy’ for the
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duration of the training session. Rather than given biofeedback, control participants were
given nature slide videos to watch for the duration of the training session. No heart rate
information was displayed on the screen and there was no mention of heart rate or
breathing during the sham session. A stress squeeze ball was issued to the participant and
used during training. If a question about this arose, they were instructed to ‘relax and
keep a clear mind’. Otherwise, no instruction, coaching or biofeedback was provided to
the participant. Home practice was administered for a minimum of 10 minutes daily,
same as the intervention group. The stress squeeze ball was recommended for use while
relaxing for the minimum time period.
HRV Measures
Resting physiological measures were recorded for 15 minutes at baseline. The use
of an autonomic testing system to precisely determine HRV at the four time periods
(baseline, post-training, booster, follow-up assessments). Testing was performed in a
standardized, recognized, and quantified manner that is non-invasive. Recording
occurred in a comfortable office setting with lights dimmed. During recording the
participants viewed nature slides and were asked to relax at baseline and in later
assessments instructed, “Do what you have been trained to do”. HRV data was obtained
via dry electrode wrist straps on both forearms of the participant, one on the right forearm
and two on the left forearm. Respiration was also monitored via a Piezo-respiratory
transducer. This data was later processed by a research assistant.
Software integrated into the HRV physiological monitoring system ran on a
laptop computer was used to complete the processing of HRV data to get time domain
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outcomes (SDNN, RMSSD), frequency outcomes (very low frequency, low frequency
and high frequency) and HRV Coherence Ratio. Processing began by de-artifacting raw
data and a 5-minute period was selected to calculate the power spectrum of HRV for each
patient (Appendix A, Figure A2). This provided data for frequency (VLF, LF, HF power,
peak frequency, peak frequency power) and time-domain HRV measures (heart rate mean
and standard deviation, NN50, pNN50, RMSSD). From these values HRV coherence is
calculated using previously acquired measures as well as new ones obtained by adjusting
the frequency bands and using the coherence equation (High_Frequency_Peak_Power /
(Total Power – High_Frequency_Peak_Power). The HRV Coherence Ratio is estimated
by calculating the ratio of power in the LF peak to the remainder of power in the
spectrum without the LF peak.29,47
Sleep Outcome Measures
The Pittsburgh Sleep Quality Index was used to measure the subjective perception
of sleep disturbances and sleep quality over the course of the past month. The PSQI
consists of 19 individual questions, addressing seven components of sleep: (a) subjective
sleep quality, (b) sleep latency, (c) sleep duration, (d) habitual sleep efficiency, (e) sleep
disturbances, (f) use of sleeping medications, and (g) daytime dysfunction (Appendix A,
Figure A3, A4 & A5). Each component receives a score between 0 and 3. The global
PSQI score is calculated by the summation of each individual component, for a total
score of 21. A score above five is indicative of poor sleep quality.9,43
Wrist actigraphy is a validated method that was used to provide a quantitative
means by which sleep disruption could be assessed. The participant was instructed to
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wear the watch consistently for 7 nights unless the watch was to be in jeopardy of getting
wet (i.e., showering, swimming, washing dishes. Weekly monitoring was performed at
baseline, post-training, and at the 8-week follow-up assessment using a standardized
protocol. AMI motionloggers (AMI, Ardsley, NY, with built-in ambient multiple
spectrum light sensor, event marker, digital watch, and off-wrist detection capability)
were used in this study. Watches were worn on the non-dominant wrist, recording
activity and light exposures at 1-minute intervals. Each participant was provided with the
wrist-worn accelerometers immediately following their baseline visit, which was returned
one week later at their first training visit. The second sleep actigraphy period was
initiated on the sixth training visit and completed at the post-training assessment. After
the follow-up assessment, rest/activity monitors were mailed back with a stamped, preaddressed box to be returned through the United States Postal Service. Participants were
provided with a sleep log and asked to manually record their sleep and wake times each
day while wearing the watch.
Actigraphy data were processed using the manufacturer’s software after
downloading the data from the AMI motionloggers to a computer. Data was processed
using ActionW 2.7 to calculate sleep duration, sleep efficiency, sleep onset latency and
wake after sleep onset. The beginning of sleep was set for each day taking into
consideration the participants sleep log, activity levels and light exposure levels
(Appendix A, Figure A6). Likewise, the end of the sleep period was set using the same
considerations. This process was completed for each of the nights a participant wore the
watch. If less than three days was recorded for any given participant, the data was
considered incomplete and was not processed or used in the analysis. The manufacturer’s
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software was used to calculate outcomes of interest during each sleep period. The sleep
variables used in this study included: sleep duration, sleep onset latency, sleep efficiency
and wake after sleep onset.
Statistical Analysis
All statistical analyses were performed using statistical analysis software
computer program (SAS version 9.4, Cary, NC). The independent variable of interest for
analysis is the change in HRV between the baseline assessment and follow-up
assessment. The group effect, the time effect and the group by time effect in the mixed
analysis was also of interest.
The effectiveness of randomization was checked to be sure all potential
confounders are equally distributed between both groups. Randomization makes
observable baseline differences unlikely, however, outcome measures and demographic
characteristics were evaluated whether differences in the groups occurred using bivariate
comparisons between treatment and control groups at baseline. Due to the small
frequency of American Indian and “Other” races in this study, the African American,
American Indian and Other participants were combined into one classification named
“Minorities.” Four individuals refused to provide race status and were not included in the
frequency count for race. Group comparisons of baseline sociodemographic, lifestyle
choices and comorbid ailments were performed using Fisher’s Exact test for categorical
variables such as sex, race and income status (PROC FREQ in SAS). For variables such
as age, the normality of the distribution was checked using PROC UNIVARIATE.
Because of the effects depression can have on an individual’s sleep the Beck’s
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Depression Index (BDI) was considered as a possible confounder for all outcomes of
interest.48 During the analysis baseline scores of BDI were adjusted for in the models
based on an a priori hypothesis.
Normally distributed data then had a test of homogeneity, F-test, to look at the
equality of variances. If the variances were equal, the pooled t-test was used and if the
variances were unequal the Satterthwaite t-test was used. If data was determined to be
not be normally distributed, a nonparametric test, the Wilcoxon signed rank test, was
used. Variables found to be statistically significantly different at baseline were
considered as a possible confounder along with baseline BDI scores.
By group and timepoint means were calculated for each assessment for the
following HRV outcome measures: SDNN, RMSSD, VLF, LF, HF and HRV Coherence
Ratio. PROC UNIVARIATE was used to check each variable for normality.
Next, to test the effect of HRV-B relative to controls, linear mixed models for
repeated measures (PROC MIXED in SAS) was used to assess the effects of intervention
group, time, and the interaction between group and time. Two-tailed p-values were used
to check baseline group comparisons as well as the Group by Time interaction term, and
changes in outcomes over time in the control group. The a priori directional hypotheses
was not applied to the control group due to no expectation of a beneficial effect. Onetailed p-values were used for a priori directional hypotheses on HRV-B intervention
effectiveness. One-tailed p-values were used in all assessments of statistical significance
due to an expectation of a directional change, based on previous literature stating the
positive effects of HRV-B on the outcomes of interest. The following covariance matrix
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structures were evaluated: compound symmetric, unstructured, and heterogeneous
compound symmetry, and the minimum Akaike Information Criterion (AIC) was used to
select the covariance matrix to be used in subsequent models. Each outcome was
evaluated separately. Demographic covariates that differed at baseline were retained in
the final model if inclusion changed the parameter estimate for the Group by Time
interaction by ≥10%. This was done until all covariates that were statistically
significantly different at baseline were checked. Covariates that were statistically
significant in the model also were retained, regardless of the effect to the parameter
estimate. The baseline score for depression (BDI) was evaluated as an a priori
confounder for sleep. Adjusted (least squares or LS) means were computed for each
group and assessment period. In addition to the overall Group by Time interaction, the
following contrasts were used to test a priori hypotheses concerning the intervention
effect: baseline versus post-training assessment, baseline versus follow-up assessment,
and, to assess treatment sustainability, post-training assessment versus follow-up
assessment.
For the PSQI Global score, this outcome was dichotomized as “good” and “poor”
sleepers using the cut point score of 5.43 This cut point has a sensitivity of 89.6% and
specificity of 86.5% for identifying individuals with sleep issues. The PROC FREQ
procedure in SAS was used to obtain the proportion of “good” and “poor” sleepers for
each group and assessment timepoint.
Finally, Cohen’s D was calculated to test effect size of the change in outcome
measures from baseline to post-training and baseline to follow-up assessment in the
intervention group. The following formula was used to calculate Cohen’s D: Cohen’s d
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= [(M2 – M1) / SDpooled]. The SDpooled was calculated using the following formula:
SDpooled = [√((SD12 + SD22) / 2)].
Missing data on baseline characteristics was limited since participants had to
provide this information to be included in the study. Missing outcome data was ignored
in the linear mixed model under the missing-at-random assumption.
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CHAPTER 4
RESULTS
Amongst the 85 patients who completed the baseline assessment, 63 further
completed the post-training assessment, 54 completed the booster assessment and 50
completed the follow-up assessment (59%). The rate of attrition by group was similar
and showed no statistically significant differences. Demographic and outcome variables
at baseline are shown in Table 4.1. Using randomization, equal proportions were
obtained for most demographic variables. Participants were primarily male (66%),
College educated (73%) and non-smokers (85%) (Table 4.1). The average age (±
standard error of the mean) for the intervention group was 54 ± 10 and 55 ± 12 in the
control group. Aside from race, there were no differences of baseline characteristics by
group (White: 37% in intervention group vs. 63% in control group, p=0.04, Table 4.1).
This potential confounder was considered when developing the final model. Due to
cancellation and rescheduling within both groups, an analysis of length of time to
complete the study by group was conducted. Without missed appointments, the study
protocol could have been completed in 112 days. On average the study protocol took 123
± 21 days. There was no difference between the groups in mean study completion time
among those who completed the protocol (124 days for the intervention group and 121
days for the control group, p=0.54, Table 4.1). Comorbid diagnoses from medical
records at baseline were evaluated as potential confounders (Table 4.1).

27

Mean HRV Coherence improved at the post-training assessment in the
intervention group compared to the baseline assessment (0.11 at baseline vs. 0.41 at posttraining, p=<0.01, Table 4.3). There was no improvement found in the control group at
post-training compared to the baseline assessment (0.10 at baseline vs. 0.08 at posttraining, p=0.67). The Group by Timepoint interaction term for the HRV Coherence
Ratio was statistically significant (t:4.21, p= <0.01). Mean HRV Coherence is improved
at follow-up assessment in the intervention group compared to baseline (0.11 at baseline
vs. 0.45 at follow-up, p=<0.01, Table 4.4). Figure 4.1 displays the improvement of the
intervention group in HRV Coherence. Figure 4.1 shows a persistence effect with a
significant improvement from baseline to post-training, but no significant changes are
observed from post-training to follow-up assessment.
Improvements in PSQI Global Score were observed, with a reduction at posttraining compared to the baseline assessment, in the intervention group (~12 at baseline
vs. ~11 at post-training, p=0.02, Table 4.2). From baseline to the follow-up assessment
of the study declines in PSQI Global Score were observed, in the intervention group.
(~12 at baseline vs. 10 at follow-up p=<0.01). There were no noteworthy effects
observed for the control group. Figure 4.2 displays the mean PSQI Global Score by
group and timepoint. Reductions in the PSQI Global Score, relative to baseline, for the
intervention group were found at post and follow-up assessments whereas no
improvement is observed in the control group, Figure 4.2. No significant differences
were observed between the post and follow-up assessment in either group for PSQI
Global Score.
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Improvements in sleep duration were observed between baseline and post-training
assessments, in the intervention group (~421 minutes at baseline vs 453 minutes at post
assessment, p=0.03, Table 4.3). Improvements for sleep duration were also observed
between baseline and follow-up assessments, in the intervention group (~ 421 minutes of
sleep per night at baseline vs. ~458 minutes of sleep per night at follow-up, p=<0.01,
Table 4.4). The group by time interaction was significant for sleep duration between
baseline and follow-up assessments (t=1.83, p=0.04). Figure 4.3 shows an increase in
minutes slept per night for the intervention group at each assessment, however this is not
observed in the control group.
There were no significant differences between baseline and post
assessments or baseline and follow-up assessment for Sleep Efficiency, in either the
intervention or control group (Table 4.3 and 4.4). Figure 4.4 displays a reduction in sleep
efficiency however it was not found to be statistically significant.
There were no significant differences, for the intervention group, between
baseline and post assessments or baseline and follow-up assessment for Sleep Onset
Latency, in either the intervention or control group (Table 4.3 and 4.4). However, the
control group did have an increase in sleep onset latency of ~2 minutes, Figure 4.5.
There were no significant differences, for the intervention group, between
baseline and post assessments or baseline and follow-up assessment for Sleep Onset
Latency, in either the intervention or control group (Table 4.3 and 4.4). Figure 4.6
displays a modest increase for both groups in the minutes awake once sleep onset has
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begun (WASO). Although a small noticeable difference is observed neither group saw a
statistically significant increase.
Using the PSQI, a clinical cut point of 5 is used to determine if an individual is a
“Good sleeper” or “Poor Sleeper”.43 In Table 4.5 the frequency of good sleepers, as
classified by the PSQI Global Score, is displayed by group and timepoint. There is an
observable increase in the proportion of individuals below the clinical cut-point from
baseline to post assessment for the intervention group (4.7% vs. 12.9%). The booster and
follow-up assessments, for the intervention group, also had a greater proportion of
individuals below the cut-point of 5 compared to baseline however, they were slightly
lower than the post assessment (Booster- 11.1%, Follow-up-12%). The control group
had an increase in the proportion of individuals below the clinical cut-point of 5 from
baseline to post assessment (2.4% vs. 6.3%). However, there is a reduction in the booster
and follow up compared to the minor improvement seen at the post assessment (Booster3.7%, Follow-up- 4%).
Cohen’s D effect size estimate was calculated for the intervention group. This
test was calculated between baseline and post assessment as well as baseline and followup assessment. Excluding coherence, at post assessment all outcome variables saw a
small effect size (d <0.3). Coherence scores experience a large effect (d=0.87).
Comparing the change from baseline to follow-up assessment coherence had a large
effect (d=1.01). PSQI and sleep duration had medium effects (PSQI d=0.47, sleep
duration d=0.42). The remaining sleep outcomes, sleep onset latency, sleep efficiency,
and wake after sleep onset, had small changes (d<0.3).
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A table for comparisons between post and follow-up assessments was not created
nor reported due to proc mixed analysis not showing any statistically significant data.
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Table 4.1: Baseline Characteristics by Group
Overall (n=85)

Intervention
(n=43)

Sham (n=41)

28 (33)
56(66)

15(34)
29 (66)

13(32)
28 (66)

49 (53)
32 (38)
54 ± 11

30 (61)
12 (37)
54 ± 10

19 (39)
20 (63)
55 ± 12

23 (27)
51 (60)
11 (13)

10 (23)
28 (63)
6 (14)

13 (32)
23 (56)
5 (12)

33 (39)
17 (20)
30 (35)
4 (5)
1 (1)
123 ± 21

15 (34)
8 (18)
18 (41)
2 (5)
1 (2)
124 ± 18

18 (44)
9 (22)
12 (29)
2 (5)
0 (0)
121 ± 23

13 (15)
72 (85)

6 (14)
38 (86)

7 (17)
34 (83)

0.57

Gender
F (%)
M (%)
Race
Minorities (%)
Caucasian (%)
Age mean ± SD
Education
≤College (%)
College (%)
Graduate School
Income
$30,000 or less
$30,000-$50,000
$50,000 or more
Refuse
Don’t know
Study Completion
In Days ± SD
Current Smoke
Yes
No
Ever Smoke
Cigarette
Yes
No
Don’t Know
Hypertension
Yes (%)
No (%)
Depression
Yes (%)
No (%)
Anxiety
Yes (%)
No (%)
PTSD

p-value

0.04
0.65
0.65

0.66

0.54
0.66
0.63

35 (41)
45 (53)
1 (1)

18 (41)
24 (55)
1 (2)

17 (41)
21 (51)
0 (0)

38 (45)
47 (55)

22 (50)
22 (50)

16 (39)
25 (61)

42 (49)
43 (51)

22 (50)
22 (50)

20 (49)
21 (51)

19 (22)
66 (78)

12 (27)
32 (73)

7 (17)
34 (83)

31 (36)
54 (64)

16 (36)
28 (64)

15 (37)
26 (63)

26 (31)
59 (69)

13 (30)
31 (70)

13 (32)
28 (68)

24 (28)
61 (72)

14 (32)
30 (68)

10 (24)
31 (76)

0.31
0.91
0.26

0.98
Yes (%)
No (%)

Sleep Disorder
Yes (%)
No (%)
Diabetes
Yes (%)
No (%)

0.83
0.45

Fisher’s exact Test (2-sided) used for categorical variables. Pooled T-test used for
continuous variables. F: Female. M: Male. SD: Standard Deviation. Study Completion
in Days: Total days to complete study from baseline visit to completion of follow-up
assessment. PTSD: Post Traumatic Stress Disorder.
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Table 4.2: Mixed model analysis of outcome variables comparing Baseline vs. Post-Training assessments
Outcome

HRV
Coherence
Ratio

SDNN

33
RMSSD

VLF Power

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

n

Post-Training
(T2)
Est µ± SE

Est. T2-T1±SE (t, p)
n

Group (t, p)
Timepoint (t, p)
Group x Timepoint (t, p)

A

0.11 ± 0.02

43

0.27 ± 0.05

31

B
Est A-B±SE
(t, p)

0.10 ± 0.02
0.01 ± 0.21
(0.15, 0.88a)

41

32

84

0.12 ± 0.02
0.15 ± 0.11
(3.36, <0.01b)

0.16 ± 0.07
(3.99, <0.01c)
0.2 ± 0.16
(0.78, 0.43d)

63

n/a

(3.08, <0.01)

A

27 ± 3

43

32 ± 3

31

(0.7, 0.24)

B

28 ± 3

41

37 ± 4

32

5 ± 0.1
(1.51, 0.07c)
9 ± 0.1
(3.15, <0.01d)

Est A-B±SE
(t, p)

-1 ± 0.1
(-0.12, 0.91a)

84

-5 ± 0.1
(-1.15, 0.13b)

63

A

17 ± 2

43

17 ± 2

31

B

17 ± 2

41

23 ± 3

32

Est A-B±SE
(t, p)

0.9 ± 0.2
(0.07, 0.47a)

84

-6 ± 0.2
(-1.73, 0.04b)

63

A

265 ± 51

43

230 ± 50

31

B

259 ± 51

41

429 ± 92

32

Est A-B±SE
(t, p)

6 ± 0.3
(0.08, 0.47a)

84

-199 ± 0.6
(-2.05, <0.01b)

63

(4.64, <0.01)
(2.59, <0.01)

(2.05, <0.01)

n/a

(0.68, 0.25)

0.9 ± 0.1
(0.16, 0.44c)
6 ± 0.08
(2.96, <0.01d)

(0.79, 0.21)
(1.33, 0.08)

n/a

(-0.9, 0.18)

-35 ± 0.2
(-0.66, 0.26c)
170 ± 0.1
(2.42, <0.01d)

(2.17, 0.02)

n/a

(-2.15,0.02)

(0.81,0.29)

Table 4.2: Mixed model analysis of outcome variables comparing Baseline vs. Post-Training assessments
Outcome

LF Power

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

n

A

168 ± 37

B

Est. T2-T1±SE (t, p)

43

Post-Training
(T2)
Est µ± SE
443 ± 106

31

170 ± 37

41

309 ± 74

32

Est A-B±SE
(t, p)

-2 ± 0.3
(-0.05, 0.48a)

84

134 ± 0.2
(1.06, 0.15b)

63

A

81 ± 19

43

70 ± 18

31

B

85 ± 20

41

156 ± 40

32

Est A-B±SE
(t, p)

-4 ± 0.3
(-0.15, 0.44a)

84

-86 ± 0.8
(-2.19, 0.02b)

63

A

12 ± 0.4

43

11 ± 0.6

31

B
Est A-B±SE
(t, p)

13 ± 0.5
-0.9 ± 0.7
(-1.42, 0.16a)

41
84

12 ± 0.6
-1 ± 9
(-1.31, 0.10b)

A

421 ± 24

37

453 ± 25

23

B
Est A-B±SE
(t, p)

431 ± 28
-10 ± 22
(-0.43, 0.67a)

33

445 ± 29
8 ± 26
(-0.32, 0.37b)

n

34
Sleep Duration

70

(1.02, 0.15)
(3.37, <0.01)
(1.29, 0.1)

n/a

HF Power

PSQI Global
Score

275 ± 0.08
(4.34, <0.01c)
139 ± 0.1
(2.69, <0.01d)

Group (t, p)
Timepoint (t, p)
Group x Timepoint (t, p)

-11 ± 0.3
(-0.61, 0.27c)
71 ± 0.1
(2.6, <0.01d)

(1.27, 0.27)
(0.86, 0.10)
(-1.18, 0.12)

n/a

32

-1 ± 0.5
(-2.06, 0.02c)
-1 ± 0.5
(-1.8, 0.07d)

(2.12, <0.01)

63

n/a

(0.21, 0.42)

(2.19, 0.02)

24

32 ± 16
(1.97, 0.03c)
14 ± 16
(0.89, 0.38d)

(1.46, 0.06)

47

n/a

(0.77, 0.22)

(0.56, 0.29)

Table 4.2: Mixed model analysis of outcome variables comparing Baseline vs. Post-Training assessments
Outcome

Sleep Efficiency

Sleep Onset
Latency

35
Wake After
Sleep Onset

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

Est. T2-T1±SE (t, p)

n

Post-Training
(T2)
Est µ± SE

n

79 ± 3

37

78 ± 3

23

B
Est A-B±SE
(t, p)

76 ± 3
4±2
(1.56, 0.12a)

33
70

75 ± 3
3±3
(1.01, 0.16b)

A

11 ± 2

37

13 ± 2

23

B
Est A-B±SE
(t, p)

10 ± 2
1 ± 0.1
(0.32, 0.75a)

33

13 ± 2
0.05 ± 0.2
(-0.17, 0.43b)

70

24

-1 ± 1
(-0.89, 0.19c)
-0.3 ± 1
(-0.21, 0.84d)

(0.56, 0.37)

47

n/a

(-0.49, 0.31)

(1.34, 0.09)

24

2 ± 0.1
(1.45, 0.08c)
3 ± 0.1
(2.06, 0.04d)

(1.76, 0.02)

47

n/a

(-0.43, 0.34)

A

82 ± 10

37

91 ± 10

23

B
Est A-B±SE
(t, p)

97 ± 11
-15 ± 9
(-1.6, 0.12a)

33

99 ± 11
-8 ± 10
(-0.79, 0.22b)

24

9±7
(1.34, 0.10c)
2±7
(0.32, 0.75d)

47

n/a

70

Group (t, p)
Timepoint (t, p)
Group x Timepoint (t, p)

(0.1, 0.46)

(0.96, 0.17)
(0.88, 0.26)
(0.72, 0.24)

LS-Means estimates displayed as mean. Larger scores represent greater HRV Coherence, Sleep Duration and Sleep
Efficiency. Greater scores of PSQI Global Score, Sleep Onset Latency and Wake After Sleep Onset display more
severe symptoms. SDNN: Standard Deviation of the Normal to Normal. RMSSD: Root Mean Square of the Successive
Differences. VLF Power: Very Low Frequency Power. LF Power: Low Frequency Power. HF Power: High Frequency
Power. a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between baseline
assessment and post-training. d2-sided comparison between baseline assessment and post-training. µ: Mean. SE:
Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: test statistic. p: p-value. Group x Timepoint: Type 3
test of fixed effects for group by timepoint interaction term (1-sided). *Adjusted for baseline depression.

Table 4.3: Mixed model analysis of outcome variables comparing Baseline vs. Post-Training assessments
Outcome

HRV
Coherence
Ratio

SDNN

36
RMSSD

VLF Power

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A
B
Est A-B±SE
(t, p)

n

Follow-up (T4)
Est µ± SE

n

0.11 ± 0.02

43

0.27 ± 0.05

25

0.10 ± 0.02
0.01 ± 0.21
(0.15, 0.88a)

41

0.12 ± 0.02
0.15 ± 0.11
(3.36, <0.01b)

84

Est. T4-T1±SE
(t, p)

25

0.16 ± 0.01
(5.13, <0.01c)
0.02 ± 0.16
(-1.0, 0.32d)

(2.19, <0.01)

50

n/a

(4.21, <0.01)

A

27 ± 3

43

31 ± 3

25

B
Est A-B±SE
(t, p)

28 ± 3
-1 ± 0.1
(-0.12, 0.91a)

41

25

84

35 ± 4
-4 ± 0.2
(-1.15, 0.13)

4 ± 0.9
(1.51, 0.07c)
7 ± 0.07
(3.15, <0.01d)

50

n/a

A

17 ± 2

43

16 ± 2

25

B
Est A-B±SE
(t, p)

17 ± 2
0.9 ± 0.2
(0.07, 0.47a)

41

19 ± 2
-3 ± 0.2
(-1.73, 0.04)

84

(4.81, <0.01)

(0.7, 0.24)
(2.05, <0.01)
(-0.1, 0.32)

25

-1 ± 1
(0.16, 0.44c)
2 ± 0.1
(2.96, <0.01d)

(1.3, 0.08)

50

n/a

(-0.14, 0.44)

A

265 ± 51

43

211 ± 49

25

B
Est A-B±SE
(t, p)

259 ± 51
6 ± 0.3
(0.08, 0.47a)

41

413 ± 96
-202 ± 0.6
(-2.05, 0.02)

25

-54 ± 0.2
(-0.66, 0.26c)
154 ± 0.1
(2.42, 0.01d)

50

n/a

84

Group (t, p)
Timepoint (t, p)
Group x Timepoint
(t, p)

(0.8, 0.21)

(2.17, 0.02)
(0.8, 0.29)
(-2.56, 0.02)

Table 4.3: Mixed model analysis of outcome variables comparing Baseline vs. Post-Training assessments
Outcome

LF Power

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A
B
Est A-B±SE
(t, p)

n

Follow-up (T4)
Est µ± SE

n

168 ± 37

43

428 ± 110

25

170 ± 37
-2 ± 0.3
(-0.05, 0.48a)

41
84

279 ± 72
149 ± 0.7
(1.06, 0.15)

81 ± 19

43

68 ± 19

25

85 ± 20
-4 ± 0.3
(-0.15, 0.44a)

41
84

109 ± 30
-41 ±0.8
(-2.19, 0.02)

25

Est A-B±SE
(t, p)

50

A

12 ± 0.6

43

10 ± 0.7

25

37
PSQI Global
Score

B
Est A-B±SE
(t, p)

13 ± 0.6
-1 ± 0.8
(-1.25, 0.8a)

41
84

13 ± 0.7
-3 ± 1
(-2.81, <0.01b)

A

421 ± 24

37

458 ± 26

21

B
Est A-B±SE
(t, p)

431 ± 28
-10 ± 22
(-0.43, 0.67a)

33

423 ± 30
35 ± 26
(1.33, 0.09b)

20

37 ± 17
(2.20, 0.02c)
-7 ± 18
(-0.42, 0.68d)

Sleep
Duration

41

n/a

25

(3.37, <0.01)

50

n/a

(1.08, 0.14)

B

70

Group (t, p)
Timepoint (t, p)
Group x Timepoint
(t, p)

260 ± 0.08
(4.34, <0.01c)
109 ± 0.1
(2.69, <0.01d)

A
HF Power

Est. T4-T1±SE
(t, p)

-13 ± 0.3
(-0.61, 0.27c)
24 ± 0.1
(2.60, <0.01d)

(1.02, 0.15)

(1.3, 0.11)
(0.9, 0.27)
(-0.39, 0.35)

25

-2 ± 0.6
(-3.55, <0.01c)
-0.5 ± 0.6
(-0.88, 0.38d)

(2.12, <0.01)

50

n/a

(-1.98, 0.02)

(2.19, 0.02)

(0.56, 0.29)
(1.46, 0.06)
(1.83, 0.04)

Table 4.3: Mixed model analysis of outcome variables comparing Baseline vs. Post-Training assessments
Outcome

Sleep
Efficiency

Sleep Onset
Latency

38
Wake After
Sleep Onset

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Follow-up (T4)
Est µ± SE

n

79 ± 3

37

78 ± 3

21

B
Est A-B±SE
(t, p)

76 ± 3
4±2
(1.56, 0.12a)

33

20

70

76 ± 3
3±3
(0.96, 0.17b)

1±2
(-0.65, 0.26c)
0.06 ± 2
(0.04, 0.97d)

41

n/a

A

10.6 ± 2

37

11.7 ± 2

21

B
Est A-B±SE
(t, p)

10.1 ± 2
1 ± 0.1
(0.32, 0.75a)

33
70

10.3 ± 2
1 ± 0.2
(0.14, 0.44b)

A

65 ± 12

37

75 ± 16

B
Est A-B±SE
(t, p)

83 ± 18
-18 ± 0.2
(-1.39, 0.17a)

33
70

81 ± 20
-6 ± 0.3
(-0.34, 0.37b)

Est. T4-T1±SE
(t, p)

Group (t, p)
Timepoint (t, p)
Group x Timepoint
(t, p)
(1.34, 0.09)
(0.56, 0.37)
(-0.48, 0.32)

20

1 ± 0.1
(0.77, 0.22c)
0.2 ± 0.1
(0.89, 0.38d)

(1.76, 0.02)

41

n/a

(-0.10, 0.46)

21

10 ± 0.1
(0.82, 0.21c)

(0.87, 0.19)

20

-2 ± 0.1
(0.66, 0.52d)

(1.28, 0.11)

41

n/a

(0.68, 0.25)

(0.1, 0.46)

LS-Means estimates displayed as mean. Larger scores represent greater HRV Coherence, Sleep Duration and Sleep
Efficiency. Greater scores of PSQI Global Score, Sleep Onset Latency and Wake After Sleep Onset display more
severe symptoms. SDNN: Standard Deviation of the Normal to Normal. RMSSD: Root Mean Square of the
Successive Differences. VLF Power: Very Low Frequency Power. LF Power: Low Frequency Power. HF Power:
High Frequency Power. a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison
between baseline assessment and post-training. d2-sided comparison between baseline assessment and posttraining. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: test statistic. p: p-value.
Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction term (1-sided). *Adjusted for
baseline depression.
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0.4

0.35

0.3

a

Coherence Ratio

a
0.25

0.2

0.15

39
0.1

0.05

0

43

41

Baseline

27

32

31
Post

27

Booster

25

25

Follow-up

Assessment
Intervention

Control

Figure 4.1: LS Means Estimates of HRV Coherence Levels by Group and Timepoint. LSMeans ± SE by treatment group and

Assessment. a1-sided, p < 0.05 vs Baseline value in the same group. n of patients within each group and assessment indicated at base
of each bar.

PSQI Global Score LS Means Estimates
16

14

12

40

Overall Sleep Quality

a
b

10

8

6

4

2

0

43

41

Baseline

31

27

32
Post

27

Booster

25

25

Follow-up

Assessment
Intervention

Control

Figure 4.2: LS Means Estimates of Pittsburg Sleep Quality Index – Global Score by Group and Timepoint. LSMeans ± SE by
treatment group and Assessment. a1-sided, p < 0.05 vs Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the
same group. N of patients within each group and assessment indicated at base of each bar. Adjusted for baseline depression.
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Figure 4.3: LS Means Estimates of Sleep Duration by Group and Timepoint. LSMeans ± SE by treatment group and Assessment. a1sided, p < 0.05 vs Baseline value in the same group. N of patients within each group and assessment indicated at base of each bar.
Adjusted for race.
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Figure 4.4: LS Means Estimates of Sleep Efficiency by Group and Timepoint. LSMeans ± SE by treatment group and Assessment. a1sided, p < 0.05 vs Baseline value in the same group. N of patients within each group and assessment indicated at base of each bar.
Adjusted for race.

Sleep Onset Latency LS Means Estimates
18

16

14

a

Minutes

12

10

8

43

6

4

2

0

37

33

23

Baseline

24
Post

21

20

Follow-up

Assessment
Intervention

Control

Figure 4.5: LS Means Estimates of Sleep Efficiency by Group and Timepoint. LSMeans ± SE by treatment group and Assessment.
LSMeans compared to Assessment 1 (1-sided, a < 0.05). Adjusted for baseline depression and race.
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Figure 4.6: LS Means Estimates of Wake After Sleep Onset by Group and Timepoint. LSMeans ± SE by treatment group and
Assessment. Adjusted for race.

Table 4.4: Proportion of Participants with good Sleep Quality by Group and Timepoint
Outcome
Group
Baseline
PostBooster
Follow-up
Training
%
n
%
n
%
n
%
n
PSQI

Intervention

4.7

2/43

12.9

4/31

11.1

3/27

12.0

3/25

Control

2.4

1/41

6.3

2/32

3.7

1/27

4.0

1/25

a

PSQI ≤5 is considered to good sleep quality. PSQI: Pittsburg Sleep Quality Index. n is
the total number of participants to complete the questionnaire within each group. 2/43:
This represents the number of participants below the cut point compared to everyone who
completed the questionnaire. i.e. 2/43 shows 2 participants scored at 5 or below out of 43
participants who completed the questionnaire at baseline for the intervention group.
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CHAPTER 5
DISCUSSION
Sleep is a vital function of the physiological process that every human being
partakes in each night. Literature has stated a loss of sleep is associated with
impairments to our attention, memory functioning, and increases of irritability and
emotional volatility.26,27 Minkel et al reported in 2012 one night of sleep loss increases
the subjective reports from participants of stress, anxiety, and anger responses towards
low stress situations.49
The prevalence of sleep disorders among veterans has continually increased since
the year 2000.50 Veterans dealing with sleep insomnia and symptoms related to reduced
or inefficient sleep can see quality of life decline as well as adverse health outcomes that
can lead to shorten life span.2,4,7,24 Medication usage often can be highly ineffective and
costly to the consumer. Further, a plethora of chronic diseases have been found to be
associated with poor sleep quality, such as, Diabetes, Cardiovascular disease, Obesity,
and depression.51–55
Balance of the ANS is paramount in the function of sleep. During the NREM
stage of sleep, the PNS becomes dominant over the SNS allowing for the body to
complete restorative processes. Parasympathetic dominance is considered to be
important for achieving restorative sleep.14 The potential benefits of HRV-B can have in
restoring balance to the ANS may be valuable in that it is a non-pharmacological
approach to the problem, it is cheap, easy to do and can be done on an as needed basis.
46

Previous studies have shown HRV-B can lead to improvements to overall sleep
quality.8,9,21
This study is one of a few to investigate the role HRV-B on improving sleep
outcomes among Veterans with chronic pain. The improvement of HRV coherence ratios
from baseline to the follow-up assessment indicates successful implementation of the
training protocol among intervention group participants. Of the 5 outcomes that were
assessed, improvements among the PSQI Global Score and sleep duration were statically
significant. The PSQI improvement is indicative of intervention group members feeling
as if they are sleeping better, longer and more efficiently through the night. The duration
of sleep improved by an average of ~40 minutes for individuals within the HRV-B group
by the follow-up assessment, the conclusion of the study. However, the improvements in
sleep quality that were subjective in nature from the PSQI were not reflected in the other
objective measures from the actiwatch data. Sleep efficiency, sleep onset latency and
wake after sleep onset did not show statically significant changes from baseline to the
post-training or follow-up assessments.
Among some studies that used HRV-B to mitigate the symptoms of poor sleep
quality, one compared the breathing technique to physical activity and a control group
(n=75). Physical activity showed a reduction in the PSQI Global score. The HRV-B
group also showed an equivalent decline in the PSQI Global score.9 Another study
completed by Laborde et al. found that slow paced breathing done for 30 days each
evening led to improvements in subjective sleep quality scores (n=64).21 Improvements
in sleep related to HRV coherence also were found by a case report (n=1) completed on
an active military member in a combat zone who suffered from sleep deprivation due to
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job stressors and used a portable biofeedback device for a total of 8 weeks. At the
conclusion of his training, the individual reported improved sleep quality as well as
reductions in depression, anxiety and sleep insomnia with practice prior to bed.12 A study
conducted on cancer patients, primarily breast cancer, showed reductions in sleep
symptoms after a maximum of 6 HRV-B training visits (n=29).56 Due to the restricted
sample sizes of the studies previously completed, interpreting the results can be difficult.
These few studies, however, are consistent with much of the literature with the effects
HRV-B can have in improving the overall sleep quality of an individual suffering from
sleep insomnia. The results from the previous studies mention as well as this current
pilot study would suggest HRV-B is a promising intervention that can be easily
implemented to mitigate the symptoms of sleep insomnia as well as be a possible
treatment option for the issue.
Insomnia is common among individuals with chronic pain as it can cause
sympathetic overactivation.26 This current pilot study showed evidence of marked
improvements in the HRV Coherence Ratio up to 2 months post-training, suggesting
increased parasympathetic activity during sleep with decreases sleep-disrupting
sympathetic activity that may have occurred due to the pain stimulus. These
improvements were seen from baseline to follow-up, and no difference was found
between the post-training assessment and the follow-up assessment. This suggests a
persistence of the HRV-B training effect and underscores the ability for these individuals
to improve their sleep and maintain that improvement through the duration of their time
spent in the study. This improvement is vital for the restorative properties of sleep to
occur which was hypothesized to improve sleep quality. The improvement in PSQI from
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baseline to follow-up assessment suggests that the increases in sleep duration were
manifested as improvements in sleep quality. The improvement of over 40 minutes in the
intervention group in the intervention group shows individuals improving from just over
7 hours of sleep to ~ a full 8 hours of sleep each night. This improvement being
attributed to HRV-B can possibly show evidence of individuals struggling to get a full
night of sleep can receive some relief by simply implementing this simple breathing
protocol to acquire some extra sleep their body may require. The lack of evidence of
improvement in sleep efficiency, sleep onset latency and wake after sleep onset may be
attributed the sample size, thus the acquisition of more participants may bolster those
trends in the data. Although a rise in the proportion of individuals below the cut point of
5 on the PSQI Global score increases, this can be seen due primarily to sparse data.
However, the shams did not exhibit this pattern of change. It is possible the individuals
who experienced improvements in sleep quality were more engaged in the home practice
prior to bedtime. The increased levels in coherence levels prior to sleep could have
reduced the sympathetic dominance prior to rest and improved sleep function. Further
investigation is required to discern what specific characteristics, if any, allowed these
individuals to improve as they did where other intervention participants did not. This
improvement could be attributed to: increased home practice, superior ability in the
technique, belief in the technique to be effective or improved self-regulation mechanics
while partaking in day to day life. Evaluation of practice time was outside the scope of
this analysis.
Limitations of this study do exist. The sample size for this study was limited to
50 participants at follow-up whereas the recruitment goal was 80. The study population
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was limited in that only Veterans of the United states military were eligible. Further,
Veterans also had to qualify by having chronic pain to be eligible. This may have limited
generalizability. In addition, over 500 participants were screen for eligibility, however,
the population could have become selective due to high prevalence of uncontrolled high
blood pressure, an exclusion criterion, and excluding medications, such as beta blockers
used to control high blood pressure. These exclusion criteria did remove many otherwise
eligible participants, however, it was necessary because blood pressure and these
medications can have direct effects on the measurement of HRV.
There were also several strengths to the study. The protocol used was one that
had been tested and used in several other studies. This study used trainers with over a
decade of experience and multiple licensing and certifications in biofeedback education.
The equipment used in this study was one of the better equipment setups available to
administer HRV-B. The study design mitigated potential confounding due to
randomization. The study design also used a 2-arm intervention which allowed for
comparison to a control group.
In conclusion, HRV-B is a nonpharmacological, easy to learn, easy to use
technique, capable of being administered as needed for self-regulation of sleep
disturbances and various other symptoms. The results displayed from this pilot study
provide evidence that HRV-B can mitigate or improve sleep quality issues. Larger,
multisite studies are needed to further evaluate the efficacy of HR-B among patients with
chronic pain or related symptoms.
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SUPPLEMENTAL MATERIALS
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Figure A.1: 16-Week Study Timeline
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Figure A.2: Instructions to calculating HRV Measures
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Figure A.3: Page 1 of 3 of the PSQI questionnaire
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Figure A.4: Page 2 of 3 of the PSQI questionnaire
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Figure A.5: Page 3 of 3 of the PSQI questionnaire
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Figure A.6: Subject Time Log for Sleep Actigraphy
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